Gentium SpA Stock Upgraded (GENT)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK ( TheStreet) -- Gentium SpA (Nasdaq: GENT) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Highlights from the ratings report include:
  • Compared to its closing price of one year ago, GENT's share price has jumped by 82.50%, exceeding the performance of the broader market during that same time frame. Regarding the stock's future course, although almost any stock can fall in a broad market decline, GENT should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
  • Despite its growing revenue, the company underperformed as compared with the industry average of 6.8%. Since the same quarter one year prior, revenues slightly increased by 4.4%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
  • GENT's debt-to-equity ratio is very low at 0.10 and is currently below that of the industry average, implying that there has been very successful management of debt levels. To add to this, GENT has a quick ratio of 1.86, which demonstrates the ability of the company to cover short-term liquidity needs.
  • The gross profit margin for GENTIUM SPA -ADR is currently very high, coming in at 84.10%. It has increased from the same quarter the previous year. Despite the strong results of the gross profit margin, GENT's net profit margin of 10.60% significantly trails the industry average.
  • Net operating cash flow has significantly decreased to -$0.05 million or 103.33% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.

Gentium S.p.A., a biopharmaceutical company, engages in the research and development of drugs derived from DNA and DNA molecules. The company has a P/E ratio of 47.1, below the average drugs industry P/E ratio of 855.9 and above the S&P 500 P/E ratio of 17.7. Gentium SpA has a market cap of $162.8 million and is part of the health care sector and drugs industry. Shares are up 78.3% year to date as of the close of trading on Friday.

You can view the full Gentium SpA Ratings Report or get investment ideas from our investment research center.

-- Written by a member of TheStreet Ratings Staff

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

Biotech 2013 by the Numbers: A Blockbuster Year

3 Biotech Stocks Spiking on Big Volume

3 Health Care Stocks Spiking on Big Volume

Trade-Ideas: Gentium SpA (GENT) Is Today's New Lifetime High Stock

4 Stocks Triggering Breakout Trades